ioQuanta Research Desk

Early OX40 combinations added little to checkpoint treatment in patients. A 2023 review examines timing, tumor recognition and drug design as possible reasons.

The review reports rising OX40 agonist patent activity, especially in 2018 and 2019, and says six candidates represented 68% of related trials.

A 67-study analysis found lower response and shorter survival among treated patients with limited daily function, but no clear difference in severe side effects.

Three people with advanced lung cancer had a striking improvement in daily function after immunotherapy. The case series cannot show how often it happens or why.

A 2021 review describes two cancer immunotherapy strategies: using antibodies to inhibit proteins on cancer cells and engineering or boosting a person's T cells.

Early trials reported tumor responses or disease control in treatment-resistant metastatic breast cancer, especially triple-negative disease; lasting patient benefit remained uncertain.

After engineered T-cell therapy, one man's lymphoma returned. Scans showed no active lymphoma during pembrolizumab, but lung inflammation cut treatment short.

A 2021 review describes camrelizumab's specified uses in China for Hodgkin lymphoma and advanced liver cancer, alongside research into other tumors.

A 2021 paper examines ways to alter fibrous tissue around tumors. One approach eased immune resistance in preclinical models without producing a lasting cure.